Finished
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
NCT01262040 · Memorial Sloan Kettering Cancer Center · Updated 7 Nov 2018
- What is being tested
- Narrow Band Imaging (NBI)
- For
- Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer; Gastrointestinal Carcinoma; Pancreatic Carcinoma; Lung Cancer; Esophageal Carcinoma
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 19 years and older. About 154 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 14 Dec 2010, ends 29 Oct 2018. Registered 17 Dec 2010.
- Results
- None posted yet.
In the researchers' words
The purpose of this study is to determine whether narrowband imaging (NBI) makes it easier for a surgeon to see cancer. NBI is a kind of light. Normally, white light is used during surgery. White light uses many wavelengths of light. NBI only uses two wavelengths which highlight the blood vessels. This makes it easier for the surgeon to see blood vessels. Tumors often have more blood vessels than normal tissue. As a result, NBI may make it easier for the surgeon to see small tumors. In this study the surgeon will look with both normal white light and NBI. This way a comparison can be made to determine which is superior. Improved identification of tumors allows doctors and patients to make informed decisions about whether treatment is needed after surgery. It also provides additional information to determine which treatments may be best.
Sites
- Memorial Sloan Kettering Cancer CenterNew York, New York, United States